Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab vs Observation in Post-CAR-T Aggressive B-Cell Lymphoma
NCT06238648Phase 2Recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jan 2024
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Academic and Community Cancer Research United. Started Jan 2024; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06238648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238648.